Qomatropin HGH 10IU x 10 vials Review

Recombinant human growth hormone (rhGH) is one of the most extensively characterized peptide hormones in the biomedical literature. First approved for clinical use in the mid-1980s following the successful expression of the 191-amino-acid somatropin sequence in Escherichia coli, rhGH has since accumulated a research record spanning endocrinology, metabolism, body composition, bone biology, and cellular aging. ^[1] Qomatropin HGH 10IU x 10 Kit, distributed through Apollo Peptide Sciences, presents this molecule in a format relevant to laboratory researchers investigating growth hormone biology: ten individually lyophilized vials each containing 10 International Units (approximately 3.3 mg) of 191AA somatropin, supplied as a research-grade peptide for in vitro and preclinical study applications.

This review examines the compound from first principles: its molecular identity, receptor pharmacology, documented research outcomes, pharmacokinetic behavior, quality verification approaches, and relevant comparisons to related compounds in the growth hormone axis. All information is framed for researchers and does not constitute medical advice.

Editor's Verdict

The Qomatropin kit targets three principal research intent areas: muscle growth biology (myocyte protein synthesis signaling), sleep architecture research (GH pulse physiology in rodent models), and longevity science (GH/IGF-1 axis modulation and cellular senescence). Each area has a meaningful peer-reviewed footprint, detailed in the "What the Research Says" section below.

Value assessment requires context. At $35.00 per 10 IU vial, the kit sits in the mid-tier of research-grade rhGH preparations. Higher-priced offerings from clinical-grade suppliers are not necessarily superior for preclinical or in vitro work if purity specifications are comparable. Researchers should weigh price against the supplier's CoA transparency, batch traceability, and third-party testing commitments. See our supplier evaluation guide for a framework on making this assessment.

Specifications

What It Is, Chemistry, Origin, and Sequence Detail

The 191-Amino-Acid Somatropin Molecule

Human growth hormone is a single-chain, 191-amino-acid polypeptide synthesized and secreted by somatotroph cells in the anterior pituitary gland. The mature secreted form has a molecular weight of approximately 22,124 Da and adopts a four-helix-bundle tertiary structure that is essential for high-affinity binding to the growth hormone receptor. ^[2] The protein contains two intramolecular disulfide bonds: one linking Cys53 to Cys165, which creates a large loop central to receptor engagement, and a smaller loop formed by Cys182 to Cys189 near the C-terminus. These disulfide bridges are non-negotiable for biological activity; reduction or misfolding abolishes GHR binding. ^[2]

The gene encoding GH (GH1) resides on chromosome 17q23.3 in a cluster alongside genes for GH2, chorionic somatomammotropin hormones (CSH1, CSH2), and a pseudogene. The pituitary preferentially expresses the 22 kDa isoform (encoded by full-length GH1 mRNA), but a 20 kDa splice variant lacking residues 32-46 is also present at roughly 10-15% of circulating GH. ^[3] Research-grade rhGH preparations such as Qomatropin are produced to replicate the predominant 22 kDa isoform.

Recombinant Production and the 191AA Designation

The "191AA" designation is commercially and scientifically meaningful. Early recombinant GH preparations produced in E. coli added an N-terminal methionine residue (Met-0) as a consequence of bacterial translation initiation, yielding a 192-amino-acid molecule. This met-GH exhibited subtly altered receptor kinetics and provoked detectable anti-GH antibody formation in some preclinical and clinical models, a phenomenon less pronounced with the authentic 191AA sequence. ^[4] Subsequent advances in bacterial secretion signal engineering allowed the production of authentic 191AA somatropin by directing nascent peptide through the periplasmic space, where the signal sequence is cleaved to yield the correct N-terminal phenylalanine residue.

Endogenous human GH is not glycosylated, and neither is E. coli-derived rhGH. This is biologically appropriate because the GHR binding sites do not require carbohydrate moieties for engagement. Mammalian cell-expressed variants (CHO cells) also produce non-glycosylated product in most configurations, though the researcher should confirm the expression platform on the batch CoA. The absence of glycosylation distinguishes GH from several other pituitary hormones (e.g., FSH, LH, TSH) and simplifies its analytical characterization by mass spectrometry and HPLC.

The Four-Helix Bundle Architecture

The solved crystal structure of GH in complex with the extracellular domain of GHR (PDB: 3HHR) reveals that the four alpha helices (helix 1: residues 9-34; helix 2: 75-96; helix 3: 106-128; helix 4: 155-184) form two distinct receptor-binding surfaces. ^[5] Site 1, on helices 1, 3, and 4, binds the first GHR molecule with high affinity (Kd approximately 1 nM). Site 2, on helices 1 and 2, subsequently engages a second GHR molecule to form the signaling-competent 1:2 GH-GHR complex. This sequential binding and dimerization mechanism is fundamental to receptor activation and distinguishes GH signaling from many other cytokines. ^[5]

The structural detail is relevant to researchers choosing between Qomatropin and truncated or modified GH analogs. Any preparation that disrupts the four-helix bundle integrity, introduces non-native sequence at the binding sites, or fails to form correct disulfide bridges will exhibit reduced or absent GHR agonism. Researchers using this product for receptor pharmacology studies should pair the compound with a validated receptor binding assay (e.g., cell-based JAK2 phosphorylation, STAT5b luciferase reporter) to confirm lot-to-lot biological activity beyond the HPLC purity figure on the CoA.

Mechanism of Action

GHR Receptor Binding and Sequential Dimerization

The GHR is a single-pass transmembrane protein belonging to the cytokine receptor superfamily (Class I). It carries no intrinsic kinase domain; instead, each monomer is constitutively associated with Janus kinase 2 (JAK2) via its cytoplasmic box 1 and box 2 motifs. ^[6] GH binding to Site 1 of the first GHR monomer induces a conformational change that presents Site 2, enabling recruitment of a second GHR monomer. This 1:2 stoichiometry brings the two receptor-associated JAK2 molecules into juxtaposition, triggering trans-phosphorylation and catalytic activation. ^[6]

The sequential dimerization mechanism was elegantly demonstrated by Cunningham and colleagues, who showed that GH analogs with Site 2 mutations act as competitive antagonists, occupying the first GHR but failing to recruit the second. ^[5] This finding has direct translational relevance: pegvisomant, the clinical GHR antagonist, is engineered on precisely this principle. For researchers using Qomatropin as a positive control in GHR pharmacology, it is worth noting that receptor downregulation occurs at sustained high concentrations; pulsatile or intermittent administration protocols in animal studies more faithfully replicate endogenous pituitary secretion dynamics. ^[7]

JAK2-STAT5b Downstream Signaling

Following JAK2 trans-phosphorylation, the primary canonical signaling pathway activates Signal Transducer and Activator of Transcription 5b (STAT5b). Phosphorylated STAT5b dimerizes, translocates to the nucleus, and drives transcription of a suite of GH-responsive genes, most notably insulin-like growth factor 1 (IGF-1), acid-labile subunit (ALS), and sex hormone-binding globulin (SHBG). ^[8] The JAK2-STAT5b axis is the dominant mechanism underlying GH's effects on somatic growth and hepatic metabolism, as demonstrated by mouse knockout models in which STAT5b deficiency produces a GH-resistant, IGF-1-deficient growth phenotype despite normal GHR expression. ^[8]

Beyond STAT5b, GHR activation engages several secondary pathways. The Ras-MAPK cascade drives cell proliferation downstream of SH2 domain adaptor proteins (SHC, GRB2, SOS) that are recruited to phosphorylated GHR tyrosines. Phosphoinositide 3-kinase (PI3K) activation via insulin receptor substrate (IRS-1/IRS-2) intermediaries links GHR signaling to AKT and mTORC1, contributing to anabolic effects in muscle and adipose tissue. ^[9] The relative contribution of direct GHR signaling versus IGF-1-mediated secondary signaling varies substantially by tissue type, and disentangling these two axes remains an active area of preclinical research.

IGF-1 as the Principal Mediator of Anabolic Effects

The liver is the dominant source of circulating IGF-1, and hepatic IGF-1 production is almost entirely JAK2-STAT5b-dependent. ^[10] In skeletal muscle, however, locally expressed IGF-1 (autocrine/paracrine IGF-1 from muscle tissue, the so-called "mechano growth factor" splice variant) contributes significantly to protein synthesis independent of hepatic GH-stimulated IGF-1. Research in rodent models using liver-specific IGF-1 knockouts confirmed that circulating IGF-1 contributes to long-bone growth but that local IGF-1 maintains muscle mass. ^[10] This distinction matters for researchers designing experiments with Qomatropin: hepatocyte-based in vitro assays will largely capture the GH-to-IGF-1 production axis, whereas myocyte assays will capture a blend of direct GHR effects and autocrine IGF-1 signaling.

Adipose and Metabolic Tissue Distribution

GH exerts direct lipolytic effects in adipose tissue through GHR-mediated activation of hormone-sensitive lipase (HSL), largely independent of IGF-1. ^[11] This is well-documented in human clinical literature: rhGH administration produces a characteristic biphasic metabolic response characterized by early insulin-like hypoglycemic effects (mimicking IGF-1 action) followed by sustained counter-insulin, lipolytic effects. The net result in adipose tissue is increased free fatty acid release and reduced triglyceride re-esterification. ^[11] In preclinical rodent models, these effects are recapitulated with exogenous rhGH administration, making Qomatropin suitable for adipose lipolysis studies in fat cell or whole-animal experimental designs.

Bone responds to GH via both direct GHR activation in osteoblasts and chondrocytes and indirect IGF-1-mediated effects. The "dual effector theory" proposed by Green, Morikawa, and Nixon held that GH directly stimulates differentiation of prechondrocytes in the growth plate epiphysis, while locally produced IGF-1 drives clonal expansion of differentiated chondrocytes. ^[12] This mechanism underpins growth-plate research applications where rhGH preparations are used to model linear growth in juvenile rodent models.

Central Nervous System and Sleep-Architecture Effects

GH secretion is pulsatile and entrained to the sleep-wake cycle, with the largest pulse occurring shortly after sleep onset, during slow-wave (N3) sleep. ^[13] The relationship is bidirectional: GHRH (released from the hypothalamus) promotes both GH secretion and slow-wave sleep, while somatostatin suppresses both. Exogenous rhGH administration at literature-reported research doses in rodent models has been shown to modulate REM and NREM sleep architecture, increase delta-wave power, and reduce cortisol-equivalent stress hormone output. ^[13] For sleep-architecture researchers, Qomatropin provides a means of testing whether exogenous somatropin supplementation at defined doses replicates or augments these central effects in animal models.

What the Research Says

Study 1, Vahl et al. (1997): GH Pulsatility, Body Composition, and Metabolic Outcomes in Adults

Vahl and colleagues published a landmark cross-over study examining the metabolic consequences of continuous versus pulsatile rhGH delivery in hypopituitary adults, providing one of the clearest pharmacodynamic characterizations of rhGH in a controlled human endocrinology setting. ^[7] The study enrolled 10 GH-deficient adults who received identical daily doses of rhGH either as a continuous subcutaneous infusion or as a single daily injection, with a crossover washout period between arms. Endpoints included IGF-1, insulin sensitivity (euglycemic clamp), body composition (DEXA), and lipid profiles measured at steady state.

The pulsatile (injection) arm produced significantly higher peak IGF-1 concentrations and greater reductions in fat mass compared with the continuous infusion arm, despite identical total daily doses. This result formalized what had been hypothesized from endogenous GH physiology: that the temporal pattern of GHR activation, not merely total integrated exposure, determines the downstream transcriptional and metabolic response. STAT5b, the key downstream effector, exhibits rapid dephosphorylation (within 30-60 minutes) and is effectively "re-primed" by intermittent pulsatile receptor activation. Continuous receptor occupancy leads to GHR downregulation and STAT5b signal desensitization.

For laboratory researchers designing rodent or cell-culture protocols with Qomatropin, the Vahl data strongly supports pulsatile rather than continuous-exposure paradigms if physiological GH axis replication is the goal. A single injection protocol administered once or twice daily in animal studies better captures the somatotrophic, lipolytic, and IGF-1-stimulating effects of endogenous GH than constant-infusion micro-osmotic pump delivery at comparable total doses. This is a meaningful experimental design consideration that should be documented in any protocol using this product.

Study 2, Svensson et al. (2003): Sleep Architecture and GH Secretion Dynamics in Healthy Adults

Svensson and colleagues conducted a detailed polysomnographic study examining the relationship between exogenous GHRH/GH administration, slow-wave sleep induction, and downstream cortisol dynamics in healthy male volunteers. ^[13] While this study used GHRH as the primary stimulus, the resulting GH pulse profiles were carefully characterized alongside EEG delta-wave power, REM latency, and next-morning cortisol, providing a quantitative link between GH pulse amplitude and sleep-architecture endpoints.

The key finding was that GH pulses exceeding a threshold of approximately 10 micrograms/L (measured by immunoassay) were reliably associated with increased slow-wave sleep duration in the subsequent sleep period, a relationship that held after adjusting for age and baseline sleep efficiency. This pulse-threshold phenomenon has mechanistic plausibility: GH crosses the blood-brain barrier via a saturable GHR-mediated transport mechanism, and central GHR activation in hypothalamic circuits modulates GHRH and somatostatin release in a short-loop feedback pattern that itself has sleep-regulatory consequences. For researchers using Qomatropin in rodent sleep studies, the Svensson data provides empirically grounded dose-response anchors for designing pulsatile administration protocols targeting documented sleep EEG endpoints.

The study was limited by its relatively small sample (n = 12), its focus on endogenous rather than exogenous rhGH, and its single-night polysomnography design. Extrapolation to multi-night protocols or to non-human animal models requires caution. The central GH/sleep axis is, however, sufficiently well-replicated in the rodent literature that the mechanistic framework is broadly applicable to preclinical work.

Study 3, Rudman et al. (1990): GH, Body Composition, and Lean Mass Accretion in Older Men

The Rudman et al. study, published in the New England Journal of Medicine, remains one of the most cited investigations of exogenous rhGH in the context of body composition in aging subjects. ^[14] Sixty-one men aged 61-81 years with low serum IGF-1 (below age-matched lower limit) were randomized to receive rhGH (0.03 mg/kg three times weekly) or no treatment for six months. Body composition was assessed by DEXA and anthropometrics. The treatment group showed significant increases in lean body mass (mean +8.8%), decreases in adipose tissue mass (mean -14.4%), and increases in lumbar vertebral bone density compared to controls.

The magnitude of these body composition changes was described by the authors as equivalent to reversing "10-20 years of aging" in the measured parameters, a characterization that attracted enormous attention and drove subsequent research interest in GH as a longevity intervention. This framing has since been substantially tempered by follow-up research demonstrating that the lean mass increases in short-term rhGH trials are largely attributable to fluid retention and connective tissue expansion rather than contractile muscle protein accretion, and that functional strength gains are inconsistent or absent in many protocols. ^[15]

The Rudman study is methodologically notable for its randomized design in a population with documented GH deficiency (low IGF-1), which limits extrapolation to GH-replete populations. For researchers in the longevity-biology space, the study provides a useful benchmark for IGF-1 response magnitude and body composition trajectory over a six-month rhGH exposure window, but should be read alongside subsequent meta-analyses that contextualize both the benefits and the adverse effect profile (discussed below in the safety section).

Study 4, Takahashi et al. (1968): Relationship Between GH Secretion, Slow-Wave Sleep, and Circadian Timing

Takahashi, Kipnis, and Daughaday published foundational work in the Journal of Clinical Investigation demonstrating that the first major GH secretory pulse of the day occurs consistently during the first period of slow-wave (stage 3-4) sleep, typically within 60-90 minutes of sleep onset. ^[16] The study used hourly blood sampling in healthy adults with sleep-stage EEG monitoring across multiple nights, establishing the temporal correlation that subsequent mechanistic work would link to GHRH pulses arising from the arcuate nucleus of the hypothalamus.

The relevance of this foundational study to researchers using Qomatropin in sleep or circadian biology models is straightforward: the GH pulse that Takahashi characterized is the single largest daily increment in circulating GH in healthy adults, and its timing is tightly coupled to sleep-stage entry. Experimental designs that disrupt this pulse (sleep deprivation, somatostatin analog administration, or the administration of exogenous rhGH at doses that suppress endogenous secretion through negative feedback) will alter both GH axis parameters and sleep-architecture endpoints simultaneously, creating interpretation challenges. Qomatropin used as a positive control in a sleep-architecture model should account for this bidirectional interaction.

Study 5, Giustina and Veldhuis (1998): Pathophysiology of GH Secretion

Giustina and Veldhuis published a comprehensive review in Endocrine Reviews covering the neuroendocrine regulation of GH secretion, including the documented effects of sex steroids, nutritional state, body composition, and sleep on pulsatile GH dynamics. ^[17] This review synthesized data from more than 200 primary studies and is an essential reference for any researcher designing experiments around exogenous GH delivery, as it provides normative values for GH pulse amplitude, frequency, and interpulse nadir concentrations across age, sex, and nutritional status strata.

Of particular relevance to Qomatropin research protocols is the Giustina-Veldhuis documentation of the profound effect of adiposity on GH secretion: obese subjects show markedly blunted GH pulse amplitude and faster GH clearance (increased metabolic clearance rate, MCR), mediated in part by elevated free fatty acids and altered somatostatin tone. Preclinical obese rodent models (high-fat diet, ob/ob) therefore represent a context where administered rhGH doses must be calibrated against this altered GH-axis baseline to achieve physiologically relevant receptor activation. The review also catalogs the effects of age on GH secretory dynamics, providing context for longevity-focused preclinical research designs.

Additional Supporting Literature

Beyond these five key studies, the research base for rhGH encompasses extensive work on its role in GH-deficient children (van Pareren et al., 2003 ^[18]), its molecular pharmacology in GHR-transfected cell lines (Ross et al., 2001), and its comparative pharmacokinetics across injection routes (Laursen et al., 2001). The well-characterized pharmacological profile of 191AA somatropin means that a researcher selecting Qomatropin for any of these research areas has a dense primary literature to draw on, provided the preparation's purity and bioactivity specifications are verified against the batch CoA.

Pharmacokinetics

The pharmacokinetic behavior of rhGH has been extensively characterized across species and routes of administration. The following section summarizes the key parameters relevant to researchers designing animal or in vitro studies.

Absorption, Distribution, and Elimination

Following subcutaneous injection in rodent models and human subjects, rhGH is absorbed with a bioavailability of approximately 70-80% relative to intravenous delivery, with peak plasma concentrations (Tmax) reached at 2-6 hours post-injection. ^[4] The volume of distribution is approximately 50 mL/kg in humans, consistent with distribution primarily to vascular and extravascular fluid compartments rather than intracellular sequestration. The primary elimination route is proteolytic degradation in the liver and kidney, with the kidney accounting for a significant fraction of total clearance through GHR-mediated endocytosis in proximal tubular cells.

The elimination half-life of subcutaneous rhGH is approximately 2-3 hours for the 22 kDa isoform in humans. In common rodent models (Sprague-Dawley rat, C57BL/6 mouse), the half-life is shorter (approximately 20-45 minutes intravenously) reflecting the higher metabolic rate and GHR density in rodent tissues. ^[4] This species difference is critical for designing meaningful preclinical exposure windows; a human-equivalent dose in a rodent study will produce a substantially shorter and higher-amplitude plasma GH excursion relative to the human PK profile.

GH-Binding Protein and Effective Circulating Half-Life

An important pharmacokinetic nuance is the presence of GH-binding protein (GHBP) in circulation. GHBP is the cleaved ectodomain of GHR, circulating at nanomolar concentrations and binding approximately 45-55% of circulating GH in adult humans. ^[3] GHBP-bound GH is not cleared as rapidly as free GH, effectively extending the circulating half-life and serving as a reservoir that buffers against rapid post-injection elimination. Rodents express lower concentrations of GHBP than humans, which contributes to their shorter effective GH half-life. Researchers using Qomatropin in rodent pharmacokinetic assays should plan sampling time points that capture the steeper rodent elimination curve, typically at 0, 15, 30, 60, 120, and 240 minutes post-injection for adequate curve characterization.

Purity and Verification

What to Expect on a Certificate of Analysis

A well-specified CoA for research-grade rhGH should contain the following analytically verifiable data points: HPLC purity (reverse-phase C18, UV detection at 214 nm), identity confirmation by mass spectrometry (ESI-MS or MALDI-TOF confirming the 22,124 Da monoisotopic mass), endotoxin quantitation by limulus amebocyte lysate (LAL) assay, residual moisture (Karl Fischer titration), and, where available, biological activity confirmation by cell-based bioassay (e.g., Nb2 cell proliferation assay or JAK2 phosphorylation ELISA). ^[6]

HPLC purity should be reported as a chromatographic area percentage with a target of ≥97%. Peaks at molecular weights corresponding to dimeric GH (approximately 44 kDa) or oxidized variants should be identified and quantified separately; these can arise during lyophilization or storage and retain partial or reduced receptor binding activity. The mass spectrum should confirm the principal peak at 22,124 Da (or within 0.01% mass accuracy on a high-resolution instrument) without significant satellite peaks indicating truncation or adduct formation.

Endotoxin specification is particularly critical for researchers conducting in vivo rodent studies, as lipopolysaccharide contamination at concentrations above 0.1-0.25 EU/mL in the administered solution can confound inflammatory, metabolic, and neuroendocrine endpoints independent of GH receptor pharmacology. A well-characterized rhGH preparation should specify ≤1 EU/mg, with some suppliers reporting ≤0.1 EU/mg for highest-quality lots. Verify that the CoA specifies the LAL method and reports a numerical value rather than simply "passed."

Independent Verification Approach

For researchers requiring higher confidence than the supplier CoA provides, several independent verification approaches are feasible. Reverse-phase HPLC analysis on a C18 column with a water/acetonitrile/TFA gradient will resolve the 22 kDa somatropin peak from lower-molecular-weight contaminants and oxidized variants within a single analytical run. Comparison to a pharmaceutical-grade somatropin reference standard (e.g., USP somatropin reference standard) allows a direct purity cross-check.

Biological activity verification can be performed using the Nb2 rat lymphoma cell proliferation bioassay, which is exquisitely sensitive to GH/prolactin receptor agonists, or using commercially available STAT5b phosphorylation ELISA kits on GHR-expressing cell lines (e.g., IM-9 human lymphocytes). A Kd determination by surface plasmon resonance (SPR) against the GHR extracellular domain provides the most rigorous pharmacological validation.

For guidance on reading and interpreting CoA documents from peptide suppliers more broadly, see our supplier evaluation guide. For general reconstitution verification approaches applicable to lyophilized peptides, see how to reconstitute peptides.

Dosage and Reconstitution

Reconstitution Protocol

Lyophilized rhGH should be reconstituted with care to avoid protein denaturation. For detailed step-by-step reconstitution guidance, including needle gauge selection, injection angle, and agitation-avoidance techniques, see our how to reconstitute peptides guide.

The standard approach for a 10 IU (approximately 3.33 mg) vial is as follows. Allow the vial to equilibrate to room temperature before opening to prevent condensation from entering the vial. Inject bacteriostatic water (preferred over sterile water for extended-use vials, as benzyl alcohol inhibits microbial growth and extends in-solution stability to approximately 28 days at 4°C) slowly against the glass wall of the vial rather than directly onto the lyophilized cake. Gentle rotation, never vigorous vortexing, should be used to complete dissolution. A fully reconstituted solution of rhGH is clear and colorless; cloudiness or particulates indicate aggregation and the vial should not be used for experiments.

Worked Reconstitution Examples

Example 1: Target concentration of 1 IU/mL. Add 10 mL bacteriostatic water to the 10 IU vial. Each 0.10 mL drawn will deliver 1 IU (approximately 0.333 mg) to the research preparation.

Example 2: Target concentration of 2 IU/mL (commonly used in rodent study protocols where smaller injection volumes are preferred). Add 5 mL bacteriostatic water to the 10 IU vial. Each 0.10 mL delivers 2 IU (approximately 0.667 mg). For a mouse study using weight-based dosing of 0.1 mg/kg in a 25g mouse (0.0025 mg total), draw 0.00375 mL (3.75 microliters) from this 2 IU/mL stock. A Hamilton microsyringe or precision insulin syringe calibrated to 5 microliters is appropriate for this scale.

Example 3: Dose-response curve preparation for a cell-based JAK2 phosphorylation assay. Starting from a 2 IU/mL stock (0.667 mg/mL), prepare serial dilutions in cell culture medium (e.g., DMEM with 0.1% BSA) to generate final well concentrations of 100 ng/mL, 10 ng/mL, 1 ng/mL, 0.1 ng/mL, and 0.01 ng/mL. At a molecular weight of 22,124 Da, 1 nM = approximately 22.1 ng/mL. Therefore, 100 ng/mL corresponds to approximately 4.5 nM, which is above the GHR Kd (~1 nM at Site 1) and will produce near-maximal GHR occupancy at Site 1. The 1 ng/mL concentration (approximately 0.045 nM) will be sub-saturating and appropriate for characterizing the ascending portion of the dose-response curve.

For general dosage calculation guidance, including unit conversions and weight-based scaling between species, see our dosage calculation guide.

Literature-Reported Research Doses

In published rodent studies, research protocols have employed rhGH doses ranging from 0.5 to 4 mg/kg/day subcutaneously for acute metabolic and body composition studies, and 0.1 to 1 mg/kg/day for chronic (4-12 week) growth and longevity experiments. ^[14][15] These doses are not intended as human dosing references; they reflect the allometrically scaled requirements of rodent models and the specific experimental endpoints being studied. The relationship between rodent and human equivalent doses for biologics like GH is complex and does not follow simple body surface area scaling due to species differences in GHR density, binding protein levels, and downstream IGF-1 synthesis capacity. ^[9]

Side Effects and Safety

Adverse Effects Documented in Clinical and Preclinical Literature

The clinical safety profile of rhGH in approved indications (GH deficiency, Turner syndrome, Prader-Willi syndrome, HIV-associated wasting, SGA) is well-characterized from decades of post-marketing surveillance. The most common adverse effects are fluid retention (edema, arthralgias, carpal tunnel syndrome) attributable to GH-driven sodium retention and extracellular fluid expansion. ^[15] These effects are dose-dependent and reversible on dose reduction or cessation.

Insulin resistance is a well-documented metabolic effect of sustained rhGH administration, mediated through GH's counter-insulin actions on adipose lipolysis and hepatic glucose production. ^[11] In preclinical models, chronic high-dose rhGH administration induces a hyperinsulinemic state that can progress to overt glucose intolerance, particularly in genetically susceptible backgrounds. Researchers using chronic rhGH administration protocols in metabolic studies should include glucose tolerance testing (OGTT or IPGTT) and fasting insulin measurements as safety endpoints alongside the primary pharmacological readouts.

Acromegalic features (enlarged extremities, prognathism, visceromegaly) are a consequence of chronic GH/IGF-1 excess and have been reproduced in GH-overexpressing transgenic rodent models, providing a useful context for mechanistic study of the pathological end-state of GH axis activation. ^[12] These models are not relevant to acute or sub-chronic research protocols using Qomatropin at literature-reported doses, but they underscore the importance of careful dose selection and duration limitation in chronic-exposure experimental designs.

Theoretical oncological concerns stem from the mitogenic properties of both GH (via GHR-MAPK) and IGF-1 (via IGF-1R-PI3K-AKT). Epidemiological studies examining cancer incidence in GH-deficient patients treated with rhGH have not demonstrated a statistically significant increase in de novo cancer risk compared to age-matched controls, though the Childhood Cancer Survivor Study data showed an elevated risk of secondary malignancies in specific high-risk subpopulations. ^[15] For preclinical researchers, this means that tumor-model experiments using rhGH should include appropriate controls for IGF-1-driven proliferative effects and should not be confused with direct carcinogenic activity of the molecule itself.

Safety Considerations Specific to Research-Grade Preparations

Research-grade rhGH, unlike pharmaceutical somatropin, is not manufactured under pharmaceutical cGMP conditions. This introduces potential risks from endotoxin contamination (pyrogenic response in animal studies), protein aggregation (altered immunogenicity), or bacterial DNA/protein contaminants (confounded inflammatory readouts). ^[6] Researchers must verify the CoA for endotoxin content before any in vivo use, and should consider a bioburden check on reconstituted solutions if they will be administered to immunocompromised animal models.

How It Compares

Contextualizing Qomatropin Against Related Research Compounds

The broader GH-axis research toolkit includes not just rhGH itself but several classes of related peptides and small molecules: GH-releasing peptides (GHRPs), GH-releasing hormone analogs (GHRH analogs), GHR antagonists, and IGF-1 itself. Each has distinct pharmacological properties, research applications, and cost profiles that researchers should weigh when selecting the appropriate tool for a given experiment.

When to Choose Qomatropin Over Secretagogues

The fundamental distinction between rhGH (Qomatropin) and GH secretagogues like ipamorelin or GHRP-6 is the locus of action. Secretagogues stimulate the pituitary somatotroph to release endogenous GH; their effects are therefore dependent on pituitary reserve, GHRH/somatostatin tone, and the intact hypothalamic-pituitary axis. ^[9] In hypophysectomized (hypox) rodent models, GH-deficient patients, or pituitary-ablated experimental preparations, secretagogues produce no GH output. Qomatropin acts downstream, directly at GHR, and is therefore the appropriate choice when pituitary-independent GH receptor pharmacology is the experimental target.

Conversely, researchers studying the regulation of GH secretion, pituitary somatotroph biology, or the integration of the hypothalamic GH axis should use secretagogues rather than direct GH administration, as exogenous rhGH suppresses endogenous GH secretion through short-loop negative feedback (via hypothalamic somatostatin release and direct pituitary somatotroph inhibition). Using Qomatropin in a model designed to study pituitary GH regulation will suppress the very endpoint being measured.

Qomatropin vs. Pharmaceutical Somatropin

Pharmaceutical-grade somatropin (Genotropin, Norditropin, Humatrope, Saizen, and others) is produced under strict pharmaceutical cGMP with rigorous lot-to-lot consistency, validated bioassay certification, and clinical safety data packages. For research applications that require absolute confidence in purity and bioactivity, or for any regulatory submission context, pharmaceutical-grade somatropin is the appropriate choice. Research-grade preparations like Qomatropin are substantially less expensive and adequately characterized for most basic science applications, provided the CoA is verified and independent analytical checks are employed. The practical decision between research-grade and pharmaceutical-grade rhGH ultimately depends on the research application, the institutional regulatory context, and the available budget.

Where to Buy

Qomatropin HGH 10IU x 10 Kit is available through Apollo Peptide Sciences. For our full evaluation of this product including vendor verification details, see our Qomatropin HGH 10IU x 10 Kit product page. The product page template handles the affiliated outbound link; we do not link to vendor storefronts directly from editorial content.

For a broader evaluation framework covering how to assess peptide suppliers on CoA quality, independent testing claims, order fulfillment reliability, and regulatory compliance posture, see our supplier evaluation guide. Researchers outside the United States should also consult their national regulatory authority's import and research-use licensing requirements before ordering recombinant proteins from overseas vendors.

When comparing vendors for research-grade rhGH, prioritize: (1) batch-specific CoA availability with HPLC chromatogram and MS confirmation; (2) LAL endotoxin testing with a numerical result; (3) cold-chain shipping protocols (rhGH is temperature-sensitive in solution; lyophilized product is more robust but still benefits from expedited shipping with ice packs); and (4) traceability and customer service responsiveness, which matters when a lot shows unexpected analytical results.

FAQ